NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Gemtuzumab Ozogamicin

Last Revision: July 20, 2020.

Estimated reading time: 1 minute

CASRN: 220578-59-6

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of gemtuzumab ozogamicin during breastfeeding. Because gemtuzumab is a large protein molecule with a molecular weight of about 152,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Vedotin (monomethyl auristatin E) is a small-molecule anticancer drug that might enter milk and be absorbed by the infant. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that women not breastfeed during treatment and for at least 1 month after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Gemtuzumab Ozogamicin

CAS Registry Number

220578-59-6

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Antineoplastic Agents, Immunological

Immunotoxins

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Similar articles in PubMed

  • Review Enfortumab Vedotin[Drugs and Lactation Database (...]
    Review Enfortumab Vedotin
    . Drugs and Lactation Database (LactMed). 2006
  • Review Loncastuximab Tesirine[Drugs and Lactation Database (...]
    Review Loncastuximab Tesirine
    . Drugs and Lactation Database (LactMed). 2006
  • Review Dostarlimab[Drugs and Lactation Database (...]
    Review Dostarlimab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Amivantamab[Drugs and Lactation Database (...]
    Review Amivantamab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Tafasitamab[Drugs and Lactation Database (...]
    Review Tafasitamab
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...